IL236465B - Pharmaceutical form for extended release of active substances - Google Patents

Pharmaceutical form for extended release of active substances

Info

Publication number
IL236465B
IL236465B IL236465A IL23646514A IL236465B IL 236465 B IL236465 B IL 236465B IL 236465 A IL236465 A IL 236465A IL 23646514 A IL23646514 A IL 23646514A IL 236465 B IL236465 B IL 236465B
Authority
IL
Israel
Prior art keywords
active substances
extended release
pharmaceutical form
pharmaceutical
extended
Prior art date
Application number
IL236465A
Other languages
Hebrew (he)
Other versions
IL236465A0 (en
Inventor
Gernot Francas
Karl-Heinz Przyklenk
Original Assignee
Hennig Arzneimittel Gmbh & Co
Gernot Francas
PRZYKLENK Karl Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hennig Arzneimittel Gmbh & Co, Gernot Francas, PRZYKLENK Karl Heinz filed Critical Hennig Arzneimittel Gmbh & Co
Publication of IL236465A0 publication Critical patent/IL236465A0/en
Publication of IL236465B publication Critical patent/IL236465B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL236465A 2012-06-25 2014-12-25 Pharmaceutical form for extended release of active substances IL236465B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012105512.2A DE102012105512A1 (en) 2012-06-25 2012-06-25 Pharmaceutical form for prolonged release of active ingredients
PCT/EP2013/063163 WO2014001268A1 (en) 2012-06-25 2013-06-24 Pharmaceutical form for extended release of active substances

Publications (2)

Publication Number Publication Date
IL236465A0 IL236465A0 (en) 2015-02-26
IL236465B true IL236465B (en) 2020-06-30

Family

ID=48670585

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236465A IL236465B (en) 2012-06-25 2014-12-25 Pharmaceutical form for extended release of active substances

Country Status (22)

Country Link
EP (1) EP2863891B1 (en)
KR (1) KR102160837B1 (en)
AU (1) AU2013283474B2 (en)
BR (1) BR112014032583B1 (en)
CA (1) CA2876294C (en)
CO (1) CO7240370A2 (en)
DE (1) DE102012105512A1 (en)
EA (2) EA028064B1 (en)
ES (1) ES2817248T3 (en)
HR (1) HRP20201534T1 (en)
HU (1) HUE050945T2 (en)
IL (1) IL236465B (en)
IN (1) IN2014MN02511A (en)
LT (1) LT2863891T (en)
MX (1) MX371143B (en)
PH (1) PH12014502834B1 (en)
PL (1) PL2863891T3 (en)
PT (1) PT2863891T (en)
RS (1) RS60872B1 (en)
SI (1) SI2863891T1 (en)
UA (1) UA116776C2 (en)
WO (1) WO2014001268A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP2959887B1 (en) * 2014-06-26 2018-11-14 Hennig Arzneimittel GmbH&Co. Kg Medication for treating dizziness due to various causes
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
JP2017531026A (en) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド Sustained release abuse deterrent liquid filler form
KR101625344B1 (en) * 2015-12-21 2016-06-08 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and duloxetine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
EP0996429B1 (en) * 1997-10-27 2003-02-05 MERCK PATENT GmbH Solid state solutions and dispersions of poorly water soluble drugs
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1701703B1 (en) * 2003-12-31 2011-03-09 Bend Research, Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102005014141B4 (en) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablet-shaped delayed-release preparation against dizziness
EP1942888A2 (en) * 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CN101049309A (en) * 2006-04-03 2007-10-10 陈茜 Cinnarizine drop pills, and preparation method
US9254268B2 (en) * 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
EP2229151B1 (en) * 2007-12-12 2012-08-08 Basf Se Salts of active ingredients with polymeric counter-ions
US20120134921A1 (en) * 2009-06-11 2012-05-31 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
WO2011024029A1 (en) * 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination
DE102011051304A1 (en) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg drug matrix
DE102011051308A1 (en) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Manufacturing process and dosage form
DE102011053068A1 (en) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Dosage form with stabilized active substance particles

Also Published As

Publication number Publication date
DE102012105512A1 (en) 2014-04-24
UA116776C2 (en) 2018-05-10
EA201792143A1 (en) 2018-05-31
BR112014032583A8 (en) 2021-06-22
KR20150041612A (en) 2015-04-16
WO2014001268A1 (en) 2014-01-03
HUE050945T2 (en) 2021-01-28
ES2817248T3 (en) 2021-04-06
AU2013283474B2 (en) 2017-12-14
AU2013283474A1 (en) 2015-01-29
PH12014502834B1 (en) 2019-12-04
BR112014032583A2 (en) 2017-06-27
LT2863891T (en) 2020-12-10
CA2876294C (en) 2020-09-08
MX371143B (en) 2020-01-20
PH12014502834A1 (en) 2015-02-02
RS60872B1 (en) 2020-11-30
EP2863891B1 (en) 2020-08-26
CA2876294A1 (en) 2014-01-03
CO7240370A2 (en) 2015-04-17
EA035815B1 (en) 2020-08-14
KR102160837B1 (en) 2020-09-29
BR112014032583B1 (en) 2022-05-17
EA201500043A1 (en) 2015-09-30
HRP20201534T1 (en) 2021-02-19
EP2863891A1 (en) 2015-04-29
PL2863891T3 (en) 2021-01-25
SI2863891T1 (en) 2020-11-30
EA028064B1 (en) 2017-10-31
IL236465A0 (en) 2015-02-26
IN2014MN02511A (en) 2015-07-17
PT2863891T (en) 2020-09-25
MX2014015642A (en) 2015-08-05

Similar Documents

Publication Publication Date Title
HUS1800035I1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL238713A0 (en) Self-regulated release of active pharmaceutical ingredient
AP2014007922A0 (en) Pharmaceutical formulations of TNF-alpha antibodies
ZA201307862B (en) Controlled release pharmaceutical dosage forms
IL236465B (en) Pharmaceutical form for extended release of active substances
ZA201409020B (en) Pharmaceutical formulation
EP2836206A4 (en) Controlled release pharmaceutical formulations of direct thrombin inhibitors
HUE036400T2 (en) Pharmaceutical composition of omeprazole
ZA201405797B (en) Pharmaceutical dosage form
GB201205164D0 (en) Pharmaceutical compounds
GB2502402B (en) Controlled drug release
IL236466A0 (en) Medicament form for release of active ingredients
IL239512A0 (en) Pharmaceutical compounds
RS64741B1 (en) Monolithic pharmaceutical form for modified release of an active ingredient combination
GB201202027D0 (en) Pharmaceutical compounds
ZA201406407B (en) Pharmaceutical formulation containing flupirtin
ZA201502354B (en) Pharmaceutical dosage form
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
GB201203253D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed